

JULY 2004 PBAC OUTCOMES - Deferrals

DRUG AND FORM	DRUG USE AND TYPE	LISTING REQUESTED BY SPONSOR	PBAC RECOMMENDATION
<p>ETANERCEPT powder for injection 25 mg, Enbrel®</p> <p>Wyeth Australia Pty Limited</p>	<p>A biological disease modifying anti-rheumatic drug for psoriatic arthritis, ankylosing spondylitis rheumatoid arthritis and polyarticular-course juvenile chronic arthritis.</p>	<p>Authority required listing</p>	<p>The PBAC deferred a decision on the listing of etanercept to seek expert advice on the appropriate wording for the restriction; and to allow the sponsor an opportunity to clarify the issues of the extent of benefit of etanercept in comparison with that gained with use of etanercept in rheumatoid arthritis.</p>
		<p><i>Sponsor's comments:</i></p>	<p>The sponsor looks forward to working with the PBAC to resolve the situation and intends to lodge a re-submission.</p>